CDMO– tag –
-
Biopharmaceutical CDMO Capacity Crunch Persists, Driving Rapid Expansion in Cell and Gene Therapy Production
Contract Pharma USA Overview The biopharmaceutical industry continues to face a CDMO capacity crunch, prompting contract development and manufacturing organizations to heavily invest in expanding production capabilities, particularly for... -
Oxford Biomedica Launches Fast-Track Viral Vector Service, Accelerating Gene Therapy Development by Cutting Manufacturing Times by up to 8 Months
Kalkine UK Overview Oxford Biomedica has launched a fast-track viral vector service to accelerate gene therapy development. This new service shortens GMP-grade manufacturing for AAV vectors from approximately 15 months to as little as 7 ... -
Texas Children’s Hospital’s GMP Facility Manufactures Over 10,000 Cell Therapy Products in 20 Years, Driving CGT Innovation
Texas Children's Hospital USA Overview Texas Children's Hospital's Center for Cell and Gene Therapy (CAGT) has manufactured over 10,000 cell therapy products and more than 70 clinical-grade viral vectors over two decades, utilizing its i... -
Biologics and GLP-1 Agonists Drive Acceleration of Automation and Digitization in Fill-Finish Manufacturing
BioProcess Online USA Overview The rapid rise of biologics—including antibody-drug conjugates (ADCs), cell & gene therapies, and mRNA products—and GLP-1 receptor agonists is accelerating the evolution of fill-finish manufacturing pro... -
Eurofins CDMO Alphora Expands Kilolab and HPAPI Manufacturing, Strengthening Integrated ADC Development
Las Vegas Sun News (via Business Wire) USA Overview Eurofins CDMO Alphora has significantly expanded its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its Mississauga, Can... -
Biopharma’s Bottleneck: Critical CDMO Capacity Shortage Hampers Advanced Therapy Development
Contract Pharma USA Overview A severe capacity crunch within Contract Development and Manufacturing Organizations (CDMOs) is impeding the biopharmaceutical industry. Recent data reveals nearly half of biopharma firms struggle to secure C... -
AsymBio Secures $184M to Scale Biologics CDMO Capacity for Advanced Therapies like ADCs and Bispecific Antibodies
Megaproject China Overview Shanghai-based biologics CDMO AsymBio has successfully raised approximately $184 million (1.24 billion RMB) from investors including Asymchem Group and Hillhouse Qirui. This substantial investment will drive th... -
Porton Advanced Secures China NMPA Drug License to Expand CDMO Services to Commercial CGT Manufacturing
Porton Advanced China Overview Porton Advanced has been granted a Class C Drug Manufacturing License by China's NMPA, enabling it to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products. This expands their... -
NueCell Bio Launches 26,300-Square-Foot Cell Therapy Development Facility to Scale CDMO Services in San Diego
PharmaSource USA Overview NueCell Bio has launched as a dedicated cell therapy science and development services company, opening a 26,300-square-foot facility in San Diego to support translational development, process development, analyt... -
Building Commercial Readiness in Advanced Therapies: Optimizing Supply Chain, Manufacturing, and Regulatory Strategy is Critical
The Medicine Maker Unknown Overview Achieving commercial readiness for Advanced Therapy Medicinal Products (ATMPs), particularly cell and gene therapy products, is an urgent industry imperative. This requires establishing robust supply c...
